Below are the most recent publications written about "Prostatic Neoplasms" by people in Profiles.
-
Zhou L, DeMarco KD, Murphy KC, Wu Z, Li J, Johnson C, Liu B, Giwa HK, Ma B, Bhalerao N, Li J, Jiang Z, Bai S, Parikh CN, Ye T, Simin K, Zhu LJ, Pitarresi JR, Wu H, Ruscetti M. p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy. Cancer Discov. 2026 Mar 02; 16(3):571-591.
-
Ortner G, Hoderlein X, Barbato F, Beyersdorff D, Bud?us L, Burger IA, Eiber M, Graefen M, Hadaschik B, Haese A, Herrmann K, Maack L, Maric I, Mattei A, Rauscher I, Salomon G, Sauer M, Schimm?ller L, Schlaefer A, Schlemmer HP, Spohn SKB, Umutlu L, Walz J, W?rnschimmel C, Koehler D, Maurer T. The Pelvic Rosetta Classification Project: An Interdisciplinary Proposal for a Lymph Node Map of the Pelvis in Prostate Cancer. J Nucl Med. 2026 Jan 02; 67(1):154-159.
-
Chowdhury SR, Parikh CN, Kaur AN, DeMarco KD, Giwa HK, Mishra AK, Murphy KC, Zhou L, Ma B, Ye T, Li J, Liu H, Bai S, Johnson C, Simin K, Pitarresi JR, Zhu LJ, Watson EV, Kelliher MA, Green MR, Fitzgerald KA, Ruscetti M. PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors. Proc Natl Acad Sci U S A. 2025 Sep 30; 122(39):e2514948122.
-
Lee D, Jeon KH, Jung J, Han K, Cho MH, Cho IY, Shin DW. Urological cancer risk in patients with rheumatoid arthritis compared to matched controls: a nationwide cohort study. Rheumatology (Oxford). 2025 Jun 01; 64(6):3458-3467.
-
De La Cerda J, Belkoff L, Courtney KD, Diamond E, D'Olimpio J, Dunshee C, Gervasi L, Goodman M, Mittal K, Morris D, Sieber P, Tutrone R, Ryan M, Zhong Y, Ufer M, Shore N. Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial. Target Oncol. 2025 May; 20(3):503-517.
-
Patel KR, Nguyen PL, Proudfoot JA, Liu Y, Pra AD, Spratt DE, Pollack A, Sandler HM, Efstathiou JA, Lawton C, Simko JP, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, Pugh SL, Davicioni E, Tran PT, Feng FY. Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials. Eur Urol Oncol. 2026 Apr; 9(2):413-421.
-
Koutroumpakis E, Patel R, Khadke S, Bedrosian A, Kumar A, Kong Y, Connell B, Upadhyay J, Dani SS, Hahn AW, Logothetis CJ, Al-Kindi S, Butler J, Nohria A, Ganatra S, Deswal A. Associations of SGLT2i with Cardiorenal Outcomes Among Diabetics with Prostate Cancer on Hormone Therapy. Cardiovasc Drugs Ther. 2025 Dec; 39(6):1343-1352.
-
Ganesan V, Steinberg RL, Trivedi H, Sorokin I, Johnson BA, Gahan JC. Scheduled intravenous ketorolac is safe and reduces narcotic use after robotic-assisted simple prostatectomy. J Robot Surg. 2024 Oct 03; 18(1):358.
-
Su XA, Stopsack KH, Schmidt DR, Ma D, Li Z, Scheet PA, Penney KL, Lotan TL, Abida W, DeArment EG, Lu K, Janas T, Hu S, Vander Heiden MG, Loda M, Boselli M, Amon A, Mucci LA. RAD21 promotes oncogenesis and lethal progression of prostate cancer. Proc Natl Acad Sci U S A. 2024 Sep 03; 121(36):e2405543121.
-
Trinh K, Chow DZ, Park H, Habib U, Offit L, Franquet E, Almeida RR, Wang Y, Borges N, Jamal F, Jacene HA, Heidari P, Ng TSC. Evaluating the Added Value of Concurrent Contrast-enhanced Diagnostic CT for PSMA-PET/CT Interpretation. Acad Radiol. 2025 01; 32(1):275-286.